Clinical trials: Hepatic Malignancies
Liver Cirrhosis, Hepatoma
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol
New strategy to improve the outcomes in patients with HCC and acute variceal bleeding. NSBB added to endoscopic ligation may further reduce rebleeding in cirrhotic patients.
- Trial name
- NCT01298284
- Testing
- propranolol
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
This is a randomized, double-blinded, controlled, phase II study. The purpose is to evaluate efficacy and safety of the combination therapy of HAIC (Hepatic arterial infusion chemotherapy) with HLX10 (PD-1 antibody) and HLX04…
- Trial name
- NCT04947826
- Testing
- HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody)
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer With Hepatic Metastases
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
- Trial name
- NCT07357220
- Testing
- VG2025, AK112
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Akeso
Hepatocellular Carcinoma
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
To determine the Maximum Tolerated Dose (MTD), and the recommended Phase 2 dose of HIA Ipilimumab in combination with IV Nivolumab by monitoring the Dose Limiting Toxicity (DLT) within 1 month after IA Ipilimumab administration…
- Trial name
- HIPANIV (NCT04823403)
- Testing
- Nivolumab, Ipilimumab
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Tumors
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of…
- Trial name
- NCT00113113
- Testing
- Rubitecan
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Hepatic Neoplasm Malignant
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
Primary Objective: To evaluate the efficacy of SECOX regimen by adding oxaliplatin plus capecitabine to sorafenib versus sorafenib alone as palliative treatment for unresectable HCC patients to prolong overall survival (OS) for…
- Trial name
- SECOX (NCT01245582)
- Testing
- oxaliplatin (SR96669), capecitabine, sorafenib
- Sponsor
- Sanofi
Colorectal Cancer
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients…
- Trial name
- DEBIRITUX (NCT01060423)
- Testing
- Cetuximab, Irinotecan, Irinotecan eluting BEADS
- Where
- 13 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Hans-Joachim Schmoll, MD
Hepatocellular Carcinoma With Portal Vein Thrombosis
Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic…
- Trial name
- NCT01659346
- Testing
- Endoscopic Variceal Ligation, Carvedilol
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-small Cell Lung Cancer, Gastric Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT05788484
- Testing
- CDX-585
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Celldex Therapeutics
Hepatocellular Carcinoma, Cirrhosis
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
- Trial name
- NCT05027425
- Testing
- Durvalumab, Tremelimumab, Liver Transplant
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Cincinnati
Liver Cancer, Surgery
Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCC
The study aims to compare the perioperative and long-term outcomes of liver resection for HBV-related HCC with versus without hepatic inflow occlusion.
- Trial name
- OHx-NOHx (NCT02563158)
- Testing
- non-occlusion technique
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Chinese PLA General Hospital
Vascular Anomalies, Hemorrhage
Safety and Efficacy Of Amber Peripheral Liquid Embolic System
A prospective, single-arm, multicenter, open-label, First-in-Human \& Pivotal Study to assess the safety and efficacy of amber SEL-P in 70 patients requiring peripheral embolization: vascular anomalies, hemorrhages, aneurysms…
- Conditions
- Vascular Anomalies, Hemorrhage, Aneurysm, Pseudoaneurysm
- Trial name
- OPAL (NCT06456125)
- Testing
- amber SEL-P Peripheral Liquid Embolic System
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- LVD Biotech S.L
Hepatocellular Carcinoma
Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)
The purpose of this study is to confirm that Ulinastatin is a safe and effective drug and it can reduce the incidence of postoperative hepatic failure in HCC patients.
- Trial name
- NCT01643447
- Testing
- Ulinastatin, Diammonium glycyrrhizinate
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatic Cancer
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis.
- Trial name
- NCT06245785
- Testing
- transarterial chemoembolisation
- Where
- 2 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Tang-Du Hospital
Carcinoma, Hepatocellular, Hepatic Insufficien
Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients
Immune checkpoint inhibitor (ICI)-based regimens (atezolizumab+bevacizumab, durvalumab+tremelimumab, nivolumab+ipilimumab) are now a first-line standard for advanced hepatocellular carcinoma (HCC).
- Conditions
- Carcinoma, Hepatocellular, Hepatic Insufficien, Disease Progression, Treatment Failure
- Trial name
- RECOMEND (NCT07514455)
- Testing
- Regorafenib (BAY 73-4506)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Ju Hyun Shim
Melanoma
A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma
Ocular melanoma, or cancer of the eye, is a rare form of cancer that can spread to the liver. A tumor in the liver, because of its size or location, sometimes cannot be removed with surgery.
- Trial name
- NCT00062933
- Testing
- Laparotomy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastatic Cancer
Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer
RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to kill their tumor cells.
- Trial name
- NCT00003433
- Testing
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine
- Where
- United States
- Sponsor
- Duke Cancer Institute
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems
Background: Paclitaxel and carboplatin are two standard drugs that stop cancer cells from reproducing. ABT-888 is an experimental cancer drug that may prevent cancer cells from "fixing" the damage done by chemotherapy drugs.
- Trial name
- NCT01419548
- Testing
- ABT-888, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
Immune checkpoint inhibitors (ICIs) plus antiangiogenic agents can achieve better efficacy than sorafenib in the treatment of hepatocellular carcinoma (HCC) within a certain period of time, but more than half of the patients are…
- Trial name
- NCT05718492
- Testing
- digital subtraction angiography., FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.